Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RuZengXiao Capsule for Mammary Gland Hyperplasia (Liver Qi Stagnation with Phlegm Stasis)
CTR20255087Phase 3Active
- Sponsor
- Heilongjiang Tianlong Pharmaceutical
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Ruzengxiao in breast hyperplasia, sponsored by Heilongjiang Tianlong Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
Ruzengxiao
03
Conditions
breast hyperplasia
Beyond the preview
Go deeper on CTR20255087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255087.